SCHEMBL3047060

SCHEMBL3047060

Cc1nc(N2CCC(Cc3ccc(OC(F)(F)F)cc3)C2=O)sc1C(=O)NCc1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ SCD O00767 17/20 0.58
▸ PPARD Q03181 1/20 0.45
▸ PPARA Q07869 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3037174 0.89 SCD (0.70) SCD
SCHEMBL3043902 0.89 SCD (0.54) SCDPPARDPPARA
SCHEMBL243087 0.84 SCD (0.80) SCD
SCHEMBL3045232 0.82 SCD (0.58) SCD
SCHEMBL3047233 0.81 SCD (0.64) SCD
SCHEMBL3049457 0.81 SCD (0.59) SCD
SCHEMBL3052612 0.80 SCD (0.62) SCD
SCHEMBL3043923 0.79 SCD (0.55) SCDPPARA
SCHEMBL3047339 0.78 SCD (0.59) SCD
SCHEMBL3038441 0.78 SCD (0.56) SCDPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236835-B2 Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG (CH) 2012-08-07 — — US claimed
US-20100029718-A1 ORGANIC COMPOUNDS NOVARTIS AG 2010-02-04 — — US claimed
US-8236835-B2 Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG (CH) 2012-08-07 — — US disclosed
US-8236835-B2 Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG (CH) 2012-08-07 — — US disclosed
US-8236835-B2 Heterocyclic inhibitors of stearoyl-CoA desaturase NOVARTIS AG (CH) 2012-08-07 — — US disclosed
US-20100029718-A1 ORGANIC COMPOUNDS NOVARTIS AG 2010-02-04 — — US disclosed
US-20100029718-A1 ORGANIC COMPOUNDS NOVARTIS AG 2010-02-04 — — US disclosed
US-20100029718-A1 ORGANIC COMPOUNDS NOVARTIS AG 2010-02-04 — — US disclosed
WO-2008036715-A1 HETEROCYCLIC ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029718-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 SCD 1/4885PPARD 33/4885PPARA 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback